AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis
AstraZeneca $AZN has divested the US rights to its preventative RSV drug, Synagis, to Swedish Orphan Biovitrum AB (Sobi) for $1.5 billion in cash and stock, as the British drugmaker continues to refine its pipeline and focus on its newer flagship products.
Synagis, known chemically as palivizumab, is used to prevent serious lower respiratory tract infections caused by the respiratory syncytial virus (RSV) in infants and young children, and is the only medicine approved for the prevention of serious RSV disease. US sales of the drug declined by 27% to $133 million in Q3, AstraZeneca reported last week. Sales of the drug outside the US, which is the responsibility of AbbVie $ABBV, were up 4% to $281 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.